First Header Logo Second Header Logo

Connection

Steven Feldman to Drug Costs

Back to Details
This is a "connection" page, showing publications Steven Feldman has written about Drug Costs.
Steven Feldman
Connection Strength
4.272
Drug Costs
  1. Johnson MC, Hamid RN, Feldman SR. The Cash Pharmacy Model May Effectively Lower Prescription Drug Prices. J Drugs Dermatol. 2020 Apr 01; 19(4):429-430.
    View in: PubMed
    Score: 0.698
  2. Stiff KM, Cline A, Feldman SR. Tracking the price of existing biologics when drugs enter the market. Expert Rev Pharmacoecon Outcomes Res. 2019 Aug; 19(4):375-377.
    View in: PubMed
    Score: 0.660
  3. Alikhan A, Daly M, Wu J, Balkrishnan R, Feldman SR. Cost-effectiveness of a hydroquinone/tretinoin/fluocinolone acetonide cream combination in treating melasma in the United States. J Dermatolog Treat. 2010 Sep; 21(5):276-81.
    View in: PubMed
    Score: 0.359
  4. Thomas K, Yelverton CB, Yentzer BA, Balkrishnan R, Fleischer AB, Feldman SR. The cost-effectiveness of rosacea treatments. J Dermatolog Treat. 2009; 20(2):72-5.
    View in: PubMed
    Score: 0.320
  5. Nelson AA, Pearce DJ, Fleischer AB, Balkrishnan R, Feldman SR. Cost-effectiveness of biologic treatments for psoriasis based on subjective and objective efficacy measures assessed over a 12-week treatment period. J Am Acad Dermatol. 2008 Jan; 58(1):125-35.
    View in: PubMed
    Score: 0.296
  6. Pearce DJ, Thomas CG, Fleischer AB, Feldman SR. The cost of psoriasis therapies: considerations for therapy selection. Dermatol Nurs. 2004 Oct; 16(5):421-8, 432.
    View in: PubMed
    Score: 0.238
  7. Payne JE, Ghamrawi RI, Lin IJ, Feldman SR. Utilization of an Online Cash-Pay Pharmacy for Topical 5-Fluorouracil Prescriptions in Older Patients. J Drugs Dermatol. 2020 May 01; 19(5):539-542.
    View in: PubMed
    Score: 0.176
  8. Aleshaki JS, Cardwell LA, Muse ME, Feldman SR. Adherence and resource use among psoriasis patients treated with biologics. Expert Rev Pharmacoecon Outcomes Res. 2018 12; 18(6):609-617.
    View in: PubMed
    Score: 0.157
  9. Feldman SR, Bagel J, Namak S. Biosimilars for Immune-Mediated Chronic Diseases in Primary Care: What a Practicing Physician Needs to Know. Am J Med Sci. 2018 May; 355(5):411-417.
    View in: PubMed
    Score: 0.149
  10. Feldman SR, Zhao Y, Zhou H, Herrera V, Tian H, Li Y. Economic Impact of Above-Label Dosing with Etanercept, Adalimumab, or Ustekinumab in Patients with Psoriasis. J Manag Care Spec Pharm. 2017 May; 23(5):583-589.
    View in: PubMed
    Score: 0.143
  11. Alghanem N, Abokwidir M, Fleischer AB, Feldman SR, Alghanem W. Variation in cash price of the generic medications most prescribed by dermatologists in pharmacies across the United States. J Dermatolog Treat. 2017 Mar; 28(2):119-128.
    View in: PubMed
    Score: 0.134
  12. Rouse NC, Farhangian ME, Wehausen B, Feldman SR. The cost-effectiveness of ustekinumab for moderate-to-severe psoriasis. Expert Rev Pharmacoecon Outcomes Res. 2015; 15(6):877-84.
    View in: PubMed
    Score: 0.128
  13. Feldman SR, Zhao Y, Shi L, Tran MH, Lu J. Economic and comorbidity burden among moderate-to-severe psoriasis patients with comorbid psoriatic arthritis. Arthritis Care Res (Hoboken). 2015 May; 67(5):708-17.
    View in: PubMed
    Score: 0.124
  14. Feldman SR, Zhao Y, Navaratnam P, Friedman HS, Lu J, Tran MH. Patterns of medication utilization and costs associated with the use of etanercept, adalimumab, and ustekinumab in the management of moderate-to-severe psoriasis. J Manag Care Spec Pharm. 2015 Mar; 21(3):201-9.
    View in: PubMed
    Score: 0.123
  15. Staidle JP, Dabade TS, Feldman SR. A pharmacoeconomic analysis of severe psoriasis therapy: a review of treatment choices and cost efficiency. Expert Opin Pharmacother. 2011 Sep; 12(13):2041-54.
    View in: PubMed
    Score: 0.095
  16. Martin S, Feldman SR, Augustin M, Szapary P, Schenkel B. Cost per responder analysis of ustekinumab and etanercept for moderate to severe plaque psoriasis. J Dermatolog Treat. 2011 Jun; 22(3):138-43.
    View in: PubMed
    Score: 0.092
  17. Lin HC, Lucas PT, Feldman SR, Balkrishnan R. Medication use and associated health care outcomes and costs for patients with psoriasis in the United States. J Dermatolog Treat. 2012 Jun; 23(3):196-202.
    View in: PubMed
    Score: 0.092
  18. Balkrishnan R, Bhosle MJ, Fleischer AB, Feldman SR. Prior authorization for topical psoriasis treatments: is it cost-beneficial for managed care? J Dermatolog Treat. 2010 May; 21(3):178-84.
    View in: PubMed
    Score: 0.088
  19. Balkrishnan R, Bhosle MJ, Camacho F, Fleischer AB, Feldman SR. Prescribing patterns for topical retinoids: analyses of 15 years of data from the national ambulatory medical care survey. J Dermatolog Treat. 2010 May; 21(3):193-200.
    View in: PubMed
    Score: 0.088
  20. Bhosle M, Balkrishnan R, Dewan T, Yelverton CB, Feldman SR. The rise of the generic drug market and its implications for dermatology. J Dermatolog Treat. 2005; 16(5-6):295-8.
    View in: PubMed
    Score: 0.061
  21. Wu JJ, Feldman SR, Rastogi S, Menges B, Lingohr-Smith M, Lin J. Comparison of the cost-effectiveness of biologic drugs used for moderate-to-severe psoriasis treatment in the United States. J Dermatolog Treat. 2018 Dec; 29(8):769-774.
    View in: PubMed
    Score: 0.038
  22. Dehkharghani S, Bible J, Chen JG, Feldman SR, Fleischer AB. The economic burden of skin disease in the United States. J Am Acad Dermatol. 2003 Apr; 48(4):592-9.
    View in: PubMed
    Score: 0.013
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.